免疫組庫定序市場：依產品類型、應用、最終用戶、地區分類

預計到 2026 年，免疫組庫定序市場價值將達到 1.811 億美元，預計到 2033 年將達到 2.63 億美元，2026 年至 2033 年的複合年成長率為 5.6%。

免疫庫是指生物體免疫系統產生的蛋白質亞型。脊椎動物免疫系統主要包含六種蛋白質：兩種免疫球蛋白和四種T細胞受體。免疫庫定序技術使研究人員和科學家能夠研究和了解涉及適應性免疫的疾病。免疫庫定序也廣泛應用於生物標記發現、感染疾病研究、氣喘和過敏研究以及癌症免疫治療。

市場動態

全球癌症發生率的不斷上升預計將推動免疫組庫定序市場的成長。根據美國國家癌症研究所（2016年）統計，美國每年新增癌症病例約1,680萬例，約59,5,690人死於癌症。此外，預計到2024年，癌症患者人數將達到1,900萬人。根據2012年《癌症地圖集》，拉丁美洲和加勒比海地區每年報告約110萬例新增癌症病例和60萬例癌症死亡病例，其中肺癌是男性和女性癌症死亡的首要原因。

然而，特定定序平台和數據分析服務的高成本以及產品召回等因素預計將在預測期內阻礙免疫組庫定序市場的成長。例如，2015年，Illumina公司召回了Illumina MiSeqDx Universal Kit 1.0，原因是該試劑盒與MiSeqDx儀器配合使用時存在軟體缺陷。軟體無法報告與引子相關的特定基因組位置的插入或缺失。

本次調查的主要特點

• 本報告詳細分析了免疫組庫定序市場、市場規模以及以 2025 年為基準年預測期（2026-2033 年）的複合年成長率（%）。
• 該報告重點介紹了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
• 該研究還提供了有關市場促進因素、限制因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
• 本報告根據以下參數對全球免疫組庫定序市場的主要參與者進行了分析：公司概況、財務表現、產品系列、地理擴張、分銷策略、關鍵發展和策略。
• 本報告的研究結果將使企業負責人和經營團隊能夠就未來的產品發布、政府措施、技術升級、市場擴張和行銷策略做出明智的決策。
• 這份全球免疫庫定序市場報告對產業內的各種相關人員很有用，包括投資者、產品製造商、經銷商、供應商、研究和諮詢公司、新參與企業和金融分析師。

目錄

第1章 研究目標與前提條件

• 調查目的
• 先決條件
• 簡稱

第2章 市場概覽

• 報告概述
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章 市場動態、監管與趨勢分析

• 市場動態
  • 促進要素
  • 抑制因素
  • 市場機遇
• 影響分析
• 市場趨勢
• 重大進展
• 監管狀態
• 產品召回
• 流行病學分析
• 技術概述
• PEST分析
• 波特五力模型

4. 2026-2033年全球免疫組庫定序市場（依產品類型分類）

• 檢測試劑盒
• T細胞受體（TCR）試劑盒
• B細胞受體（BCR）試劑盒
• 裝置

5. 2026-2033年全球免疫組庫定序市場（依應用領域分類）

• 癌症免疫療法
• 生物標記發現
• 自體免疫疾病
• 疫苗研發與療效
• 移植排斥與耐受
• 感染疾病
• 其他用途

6. 2026-2033年全球免疫組庫定序市場（依最終用戶分類）

• 診斷檢查室
• 生物技術和製藥公司
• 學術和研究機構
• 其他

7. 2026-2033年全球免疫組庫定序市場（按地區分類）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
• 亞太地區
  • 中國
  • 日本
  • 印度
  • ASEAN
  • 澳洲
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲國家
• 非洲
  • 北非
  • 中非
  • 南非
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東國家

第8章 競爭情勢

• 公司簡介
  • Thermo Fisher Scientific, Inc.
  • Illumina Inc.
  • ArcherDX, Inc.
  • Roche Holding AG
  • Pacific Biosciences
  • CD Genomics
  • Atreca, Inc.
  • Adaptive Biotechnologies
  • Oxford Nanopore Technologies, Ltd.
  • Qiagen NV
  • Agilent Technologies, Inc.
  • Takara Bio, Inc.

第9章各節

• 參考
• 調查方法

Immune Repertoire Sequencing Market is estimated to be valued at USD 181.1 Mn in 2026 and is expected to reach USD 263.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.6% from 2026 to 2033.

Immune repertoire refers to sub-type protein that an organism's immune system creates. Immune systems in vertebrates have six key types of proteins- two immunoglobulin and four T cell receptors. Immune repertoire sequencing enables researchers and scientists to examine and understand adaptive immune-mediated diseases. Immune repertoire sequencing is also widely applicable in biomarker discovery, infectious disease research, asthma and allergy research, and cancer immunotherapy.

Market Dynamics

Increasing prevalence of cancer worldwide is expected to boost immune repertoire sequencing market growth. According to National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer were diagnosed in the U.S., with around 595,690 deaths from the disease. Moreover, the number of people suffering from cancer is expected to reach to 19 million by 2024. According to the Cancer Atlas, 2012, about 1.1 million new cancer cases and 600,000 cancer deaths are reported annually in Latin America and the Caribbean, where lung cancer is the leading cause of cancer death for both sexes.

However, factors such as high cost associated with certain sequencing platforms and data analytic services coupled with product recalls are expected to hinder growth of the immune repertoire sequencing market during the forecast period. For instance, in 2015, Illumina Inc. recalled its Illumina MiSeqDx Universal Kit 1.0, due to software limitation when using the product on MiSeqDx instrument. The software could not report insertions or deletions at specific genomic locations with respect to the primer.

Key features of the study

• This report provides in-depth analysis of the immune repertoire sequencing market, market size (USD Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2026 - 2033, considering 2025 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global immune repertoire sequencing market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include Thermo Fisher Scientific, Inc., Illumina Inc., ArcherDX, Inc., Roche Holding AG, Pacific Biosciences, CD Genomics, Atreca, Inc., Adaptive Biotechnologies, Oxford Nanopore Technologies, Ltd., Qiagen N.V., Agilent Technologies, Inc., and Takara Bio, Inc.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global immune repertoire sequencing market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for immune repertoire sequencing market, research and consulting firms, new entrants, and financial analysts

Market Segmentation

• By Product Type
  • Assay Kits
  • T-Cell Receptor (TCR) Kits
  • B-Cell Receptor (BCR) Kits
  • Instruments
• By Application
  • Cancer Immunotherapy
  • Biomarker Discovery
  • Autoimmune Diseases
  • Vaccine Development and Efficacy
  • Transplant Rejection and Tolerance
  • Infectious Diseases
  • Other Applications
• By End User
  • Diagnostic Labs
  • Biotechnology and Pharmaceutical Companies
  • Academic and Research Institutes
  • Others
• By Region
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa
  • GCC Countries
  • Israel
  • Rest of Middle East & Africa
• Key Players Insights
  • Thermo Fisher Scientific, Inc.,
  • Illumina Inc.
  • ArcherDX, Inc.
  • Roche Holding AG
  • Pacific Biosciences
  • CD Genomics, Atreca, Inc.
  • Adaptive Biotechnologies
  • Oxford Nanopore Technologies, Ltd.
  • Qiagen N.V.
  • Agilent Technologies, Inc.
  • Takara Bio, Inc.

Table of Contents

1. Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Product Type
  • Market Snippet, By Application
  • Market Snippet, By End User
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Landscape
• Product Recall
• Epidemiology Analysis
• Technology Overview
• PEST Analysis
• Porter's Five Forces model

4. Global Immune Repertoire Sequencing Market, By Product Type, 2026 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Assay Kits
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• T-Cell Receptor (TCR) Kits
• B-Cell Receptor (BCR) Kits
• Instruments
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)

5. Global Immune Repertoire Sequencing Market, By Application, 2026 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Cancer Immunotherapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Biomarker Discovery
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Autoimmune Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Vaccine Development and Efficacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Transplant Rejection and Tolerance
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Infectious Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Other Applications
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)

6. Global Immune Repertoire Sequencing Market, By End User, 2026 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Diagnostic Labs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Biotechnology and Pharmaceutical Companies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Academic and Research Institutes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)

7. Global Immune Repertoire Sequencing Market, By Region, 2026 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, By Region, 2026 - 2033
  • Regional Trends
• North America
  • Market Size and Forecast, By Product Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By End User, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
    • U.S.
    • Canada
• Europe
  • Market Size and Forecast, By Product Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By End User, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Product Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By End User, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Market Size and Forecast, By Product Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By End User, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Africa
  • Market Size and Forecast, By Product Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By End User, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa
• Middle East
  • Market Size and Forecast, By Product Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By End User, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East

8. Competitive Landscape

• Company Profiles
  • Thermo Fisher Scientific, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Illumina Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • ArcherDX, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Roche Holding AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Pacific Biosciences
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • CD Genomics
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Atreca, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Adaptive Biotechnologies
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Oxford Nanopore Technologies, Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Qiagen N.V.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Agilent Technologies, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Takara Bio, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Analyst Views

9. Section

• References
• Research Methodology
• About Us and Sales Contact